Literature DB >> 32041836

Extensive clonal branching shapes the evolutionary history of high-risk pediatric cancers.

Natalie Andersson1, Bjorn Bakker2, Jenny Karlsson3, Anders Valind1, Linda Holmquist Mengelbier4, Diana C J Spierings5, Floris Foijer6, David Gisselsson7.   

Abstract

Darwinian evolution of tumor cells remains underexplored in childhood cancer. We here reconstruct the evolutionary histories of 56 pediatric primary tumors, including 24 neuroblastomas, 24 Wilms tumors and 8 rhabdomyosarcomas. Whole genome copy number and whole exome mutational profiling of multiple regions per tumor was performed followed by clonal deconvolution to reconstruct a phylogenetic tree for each tumor. Overall, 88% of the tumors exhibited genetic variation among primary tumor regions. This variability typically emerged through collateral phylogenetic branching, leading to spatial variability in the distribution of more than 50% (96/173) of detected diagnostically informative genetic aberrations. Single cell sequencing of 547 individual cancer cells from eight solid pediatric tumors confirmed branching evolution to be a fundamental underlying principle of genetic variation in all cases. Strikingly, cell-to-cell genetic diversity was almost twice as high in aggressive compared to clinically favorable tumors (median Simpson index of diversity 0.45 vs. 0.88; p=0.029). Similarly, a comparison of multiregional sampling data from a total of 274 tumor regions showed that new phylogenetic branches emerge at a higher frequency per sample and carry a higher mutational load in high-risk than in low-risk tumors. Timelines based on spatial genetic variation showed that the mutations most influencing relapse risk occur at initiation of clonal expansion in neuroblastoma and rhabdomyosarcoma, while in Wilms tumor they are late events. Thus, from an evolutionary standpoint, some high-risk childhood cancers are born bad, while others grow worse over time.
Copyright ©2020, American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32041836     DOI: 10.1158/0008-5472.CAN-19-3468

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Finding the way to Wilms tumor by comparing the primary and relapse tumor samples.

Authors:  Filippo Spreafico; Sara Ciceri; Daniela Perotti
Journal:  Cell Rep Med       Date:  2022-06-21

Review 2.  Pediatric Sarcomas: The Next Generation of Molecular Studies.

Authors:  Petros Giannikopoulos; David M Parham
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

3.  DEVOLUTION-A method for phylogenetic reconstruction of aneuploid cancers based on multiregional genotyping data.

Authors:  Natalie Andersson; Subhayan Chattopadhyay; Anders Valind; Jenny Karlsson; David Gisselsson
Journal:  Commun Biol       Date:  2021-09-20

4.  Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.

Authors:  Karin Schmelz; Joern Toedling; Matt Huska; Maja C Cwikla; Louisa-Marie Kruetzfeldt; Jutta Proba; Peter F Ambros; Inge M Ambros; Sengül Boral; Marco Lodrini; Celine Y Chen; Martin Burkert; Dennis Guergen; Annabell Szymansky; Kathy Astrahantseff; Annette Kuenkele; Kerstin Haase; Matthias Fischer; Hedwig E Deubzer; Falk Hertwig; Patrick Hundsdoerfer; Anton G Henssen; Roland F Schwarz; Johannes H Schulte; Angelika Eggert
Journal:  Nat Commun       Date:  2021-11-23       Impact factor: 14.919

5.  Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis.

Authors:  Christina Siesing; Alexandra Petersson; Thora Ulfarsdottir; Subhayan Chattopadhyay; Björn Nodin; Jakob Eberhard; Jenny Brändstedt; Ingvar Syk; David Gisselsson; Karin Jirström
Journal:  Mod Pathol       Date:  2022-02-15       Impact factor: 8.209

6.  Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development.

Authors:  Marina Danilenko; Masood Zaka; Claire Keeling; Stephen Crosier; Stephanie Lyman; Martina Finetti; Daniel Williamson; Rafiqul Hussain; Jonathan Coxhead; Peixun Zhou; Rebecca M Hill; Debbie Hicks; Vikki Rand; Abhijit Joshi; Edward C Schwalbe; Simon Bailey; Steven C Clifford
Journal:  Acta Neuropathol       Date:  2022-07-13       Impact factor: 15.887

7.  Tracing the evolution of aneuploid cancers by multiregional sequencing with CRUST.

Authors:  Subhayan Chattopadhyay; Jenny Karlsson; Anders Valind; Natalie Andersson; David Gisselsson
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

8.  Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma.

Authors:  Santiago Zugbi; Daiana Ganiewich; Arpita Bhattacharyya; Rosario Aschero; Daniela Ottaviani; Claudia Sampor; Eduardo G Cafferata; Marcela Mena; Mariana Sgroi; Ursula Winter; Gabriela Lamas; Mariona Suñol; Manuel Daroqui; Edgardo Baialardo; Beatriz Salas; Anirban Das; Adriana Fandiño; Jasmine H Francis; Fabiana Lubieniecki; Cinzia Lavarino; Ralph Garippa; Osvaldo L Podhajcer; David H Abramson; François Radvanyi; Guillermo Chantada; Andrea S Llera; Paula Schaiquevich
Journal:  Cancers (Basel)       Date:  2020-09-22       Impact factor: 6.639

9.  Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?

Authors:  Anders Valind; David Gisselsson
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-01

10.  Spatial structure governs the mode of tumour evolution.

Authors:  Robert Noble; Dominik Burri; Cécile Le Sueur; Jeanne Lemant; Yannick Viossat; Jakob Nikolas Kather; Niko Beerenwinkel
Journal:  Nat Ecol Evol       Date:  2021-12-23       Impact factor: 19.100

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.